Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease

Sang Hyoung Park; Badr Al-Bawardy; Satimai Aniwan; Sunanda V. Kane; Nayantara Coelho-Prabhu; Konstantinos A. Papadakis; John B. Kisiel; David H. Bruining; William A. Faubion; Laura E. Raffals; Darrell S. Pardi; William J. Tremaine; Michael C. Stephens; Jeanne Tung; Sahil Khanna; Maria Alice V. Willrich; Edward V. Loftus

doi:10.1093/crocol/otz047

Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease

Sang Hyoung Park, Badr Al-Bawardy, Satimai Aniwan, Sunanda V. Kane, Nayantara Coelho-Prabhu, Konstantinos A. Papadakis, John B. Kisiel, David H. Bruining, William A. Faubion, Laura E. Raffals, Darrell S. Pardi, William J. Tremaine, Michael C. Stephens, Jeanne Tung, Sahil Khanna, Maria Alice V. Willrich, Edward V. Loftus

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background and Aims: We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods: We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results: A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions: Higher cutoff ATL was associated with endoscopic and/or radiologic response.

Original language	English (US)
Journal	Crohn's and Colitis 360
Volume	1
Issue number	3
DOIs	https://doi.org/10.1093/crocol/otz047
State	Published - Oct 1 2019

Keywords

Adalimumab
Inflammatory bowel disease
Therapeutic drug monitoring

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1093/crocol/otz047

Cite this

Park, S. H., Al-Bawardy, B., Aniwan, S., Kane, S. V., Coelho-Prabhu, N., Papadakis, K. A., Kisiel, J. B., Bruining, D. H., Faubion, W. A., Raffals, L. E., Pardi, D. S., Tremaine, W. J., Stephens, M. C., Tung, J., Khanna, S., Willrich, M. A. V., & Loftus, E. V. (2019). Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease. Crohn's and Colitis 360, 1(3). https://doi.org/10.1093/crocol/otz047

Park, SH, Al-Bawardy, B, Aniwan, S, Kane, SV, Coelho-Prabhu, N, Papadakis, KA , Kisiel, JB, Bruining, DH, Faubion, WA , Raffals, LE, Pardi, DS, Tremaine, WJ, Stephens, MC, Tung, J, Khanna, S, Willrich, MAV & Loftus, EV 2019, 'Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease', Crohn's and Colitis 360, vol. 1, no. 3. https://doi.org/10.1093/crocol/otz047

@article{32ad3608bc4b44fa8409758b67ca388b,

title = "Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease",

abstract = "Background and Aims: We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods: We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results: A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions: Higher cutoff ATL was associated with endoscopic and/or radiologic response.",

keywords = "Adalimumab, Inflammatory bowel disease, Therapeutic drug monitoring",

author = "Park, {Sang Hyoung} and Badr Al-Bawardy and Satimai Aniwan and Kane, {Sunanda V.} and Nayantara Coelho-Prabhu and Papadakis, {Konstantinos A.} and Kisiel, {John B.} and Bruining, {David H.} and Faubion, {William A.} and Raffals, {Laura E.} and Pardi, {Darrell S.} and Tremaine, {William J.} and Stephens, {Michael C.} and Jeanne Tung and Sahil Khanna and Willrich, {Maria Alice V.} and Loftus, {Edward V.}",

note = "Publisher Copyright: {\textcopyright} 2019 Crohn's & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.",

year = "2019",

month = oct,

day = "1",

doi = "10.1093/crocol/otz047",

language = "English (US)",

volume = "1",

journal = "Crohn's and Colitis 360",

issn = "2631-827X",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease

AU - Park, Sang Hyoung

AU - Al-Bawardy, Badr

AU - Aniwan, Satimai

AU - Kane, Sunanda V.

AU - Coelho-Prabhu, Nayantara

AU - Papadakis, Konstantinos A.

AU - Kisiel, John B.

AU - Bruining, David H.

AU - Faubion, William A.

AU - Raffals, Laura E.

AU - Pardi, Darrell S.

AU - Tremaine, William J.

AU - Stephens, Michael C.

AU - Tung, Jeanne

AU - Khanna, Sahil

AU - Willrich, Maria Alice V.

AU - Loftus, Edward V.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Background and Aims: We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods: We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results: A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions: Higher cutoff ATL was associated with endoscopic and/or radiologic response.

AB - Background and Aims: We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods: We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results: A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions: Higher cutoff ATL was associated with endoscopic and/or radiologic response.

KW - Adalimumab

KW - Inflammatory bowel disease

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=85086025052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086025052&partnerID=8YFLogxK

U2 - 10.1093/crocol/otz047

DO - 10.1093/crocol/otz047

M3 - Article

AN - SCOPUS:85086025052

SN - 2631-827X

VL - 1

JO - Crohn's and Colitis 360

JF - Crohn's and Colitis 360

IS - 3

ER -

Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this